Details for Patent: 9,206,135
✉ Email this page to a colleague
Which drugs does patent 9,206,135 protect, and when does it expire?
Patent 9,206,135 protects APTIOM and is included in one NDA.
This patent has twenty-seven patent family members in twenty-one countries.
Summary for Patent: 9,206,135
| Title: | Asymmetric catalytic reduction of oxcarbazepine |
| Abstract: | A process for preparing (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide or (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a hydride source is disclosed. The catalyst is prepared from a combination of [RuX.sub.2(L)].sub.2 wherein X is chlorine, bromine or iodine, and L is an aryl or aryl-aliphatic ligand, with a ligand of formula (A) or formula (B): ##STR00001## wherein R.sup.1 is chosen from C.sub.1-6 alkoxy and C.sub.1-6 alkyl, n is a number from 0 to 5, and when n is a number from 2 to 5, R.sup.1 can be the same or different, and R.sup.2 is alkyl, substituted alkyl, aryl, substituted aryl, alkaryl or substituted alkaryl. The hydride source is either NR.sup.3R.sup.4R.sup.5 and formic acid, [R.sup.3R.sup.4R.sup.5NH][OOCH] and optionally formic acid, or [M][OOCH].sub.x and formic acid, wherein R.sup.3, R.sup.4 and R.sup.5 are C.sub.1-6 alkyl, M is an alkali metal or alkaline earth metal and x is 1 or 2. A pH from 6.5 to 8 is maintained during the process. |
| Inventor(s): | Learmonth; David Alexander (Alfena, PT), Grasa; Gabriela Alexandra (Mantua, NJ), Zanotti-Gerosa; Antonio (Cambridge, GB) |
| Assignee: | Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT) |
| Application Number: | 13/651,844 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,206,135 |
|
Patent Claim Types: see list of patent claims | Compound; Process; Use; |
Drugs Protected by US Patent 9,206,135
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-001 | Nov 8, 2013 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-002 | Nov 8, 2013 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sumitomo Pharma Am | APTIOM | eslicarbazepine acetate | TABLET;ORAL | 022416-003 | Nov 8, 2013 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,206,135
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0515690.6 | Jul 29, 2005 |
International Family Members for US Patent 9,206,135
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1915346 | ⤷ Sign Up | C01915346/01 | Switzerland | ⤷ Sign Up |
| Argentina | 055917 | ⤷ Sign Up | |||
| Austria | E520665 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
